Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
Dabigatran (DAB) is an orally administered thrombin inhibitor. Both DAB and its main metabolite dabigatran acylglucuronide (DABG) have established anticoagulant effects. Here, we aimed to compare the relative anticoagulant effects of DABG and DAB in humans. Anticoagulant effects of DAB and DABG were...
Saved in:
Main Authors: | Jong-Min Kim (Author), Jihyeon Noh (Author), Jin-Woo Park (Author), Hyewon Chung (Author), Kyoung-Ah Kim (Author), Seung Bin Park (Author), Jun-Seok Lee (Author), Ji-Young Park (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects
by: Hyewon Chung, et al.
Published: (2023) -
The Discovery of Dabigatran Etexilate
by: Joanne evan Ryn, et al.
Published: (2013) -
Pharmacokinetics and Pharmacogenetics of Dabigatran
by: A. V. Savinova, et al.
Published: (2021) -
Dabigatran etexilate - A novel oral anticoagulant for bleeding complications
by: Himabindu Reddy, et al.
Published: (2015) -
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
by: Sié P
Published: (2016)